Summary
Cannot audit the AI-generated response for alignment with FDA-approved prescribing information because the actual AI response text was not provided; only a list of claims was provided, and several claims (especially economic/formulary substitution statements) are not supported or not verifiable from the provided label excerpts.
Category Scores
Accurate Statements
Breo Ellipta contains fluticasone furoate and vilanterol.
Supported by label description: Section 11 (Description) indicates BREO ELLIPTA is a combination of fluticasone furoate (ICS) and vilanterol (LABA).
Breo Ellipta is a maintenance inhaler for COPD.
Supported by label indications: Section 1.1 states BREO ELLIPTA is indicated for maintenance treatment of COPD.
Breo Ellipta is used for asthma in some patients.
Partially supported by label indications: Section 1.2 indicates maintenance treatment of asthma in patients aged 5 years and older (the claim is nonspecific but aligned).
Unsupported Statements
A cheaper alternative to Breo is typically another inhaler product that uses the same active ingredients and dose (or an officially interchangeable alternative).
Not addressed in the provided label excerpts; no label support for interchangeability/economic claims.
Cheaper alternatives may include other generic or brand-name inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combinations.
Not addressed in the provided label excerpts; the label does not discuss pricing or specific substitution categories as 'cheaper alternatives.'
Sometimes a different device strength or formulation can be substituted by a clinician based on the prescribed dose.
Not addressed in the provided label excerpts; dose/strength substitution guidance is not provided in the supplied text beyond recommended dosing for specific strengths.
Generic versions of Breo (fluticasone furoate + vilanterol) are usually the lowest-cost option when available where the patient lives.
Economic/pricing claim not supported by the provided label excerpts.
When generic versions are not available, insurers and pharmacies may steer patients to a different ICS/LABA inhaler that is preferred on the patient’s plan.
Insurer/pharmacy steering and formulary preference practices are not described in the provided label excerpts.
Many formularies cover other ICS/LABA inhalers for COPD/asthma maintenance in place of Breo.
Formulary coverage/practices are not addressed in the provided label excerpts.
A typical therapeutic alternative category is another inhaled corticosteroid (ICS) plus a long-acting beta agonist (LABA) combination.
The label excerpts do not list therapeutic alternatives or substitution categories.
A prescriber can match a therapeutic alternative to the patient’s diagnosis (COPD vs asthma), the patient’s current Breo strength, and symptom control.
Label excerpts provided do not describe how to select alternative therapies or match alternatives by these factors.
A pharmacist can check discount cards, manufacturer programs (where offered), and insurance preferred-tier substitutions and compare them against the cost of alternative ICS/LABA inhalers.
Label excerpts do not address discount cards, manufacturer programs, or cost-comparison workflows.
Contradictions
Important Omissions
Use limitations for acute bronchospasm/rescue therapy (e.g., 'not indicated for relief of acute bronchospasm' and 'should not be used for the relief of acute symptoms/rescue therapy') were not included in the provided AI claim list.
Importance:
Moderate
Key safety warnings relevant to safe use (e.g., not initiating during rapidly deteriorating episodes; excessive use; pneumonia; paradoxical bronchospasm; hypersensitivity; cardiovascular effects; orofaryngeal candidiasis; pediatric growth monitoring) were not included in the provided AI claim list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-supported claims relate to ingredients and general maintenance indications. However, the majority of claims are about substitution/cost/insurer practices that are not supported by label excerpts; absence of label-specific safety/limitation statements increases the likelihood of omission-related misunderstanding, though no direct contradiction to label text is evident from the provided claim list.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Claims about pricing, formulary steering, interchangeability, therapeutic alternatives, and pharmacist workflows are not supported by the provided FDA label excerpts and cannot be verified against them.
Suggested Improvement
Limit statements to label-supported information (ingredients and approved indications/limitations such as not for acute bronchospasm) and remove or qualify non-label economic/substitution/insurer claims unless supported by label text.